t. cruzi type ii
DESCRIPTION
Proposed candidate materials and results of the feasibility studies for a WHO serological reference panel. T. cruzi type II. Márcia Otani Fundação Pró-Sangue Hemocentro de São Paulo. Raw material Epidemiological data. 4 y 5. 3. 1. 2. 3. Epidemiological Questionnaire. - PowerPoint PPT PresentationTRANSCRIPT
Proposed candidate materials and Proposed candidate materials and results of the feasibility studies for a results of the feasibility studies for a WHO serological reference panelWHO serological reference panel
T.T.cruzicruzi type II type II
Márcia OtaniMárcia OtaniFundação Pró-Sangue Hemocentro de São PauloFundação Pró-Sangue Hemocentro de São Paulo
Raw materialRaw material Epidemiological dataEpidemiological data
ID Age Gender State Collected date
Plasma volume
1 103362946 31 Female Minas Gerais
Januaria, for 28 years
2007-02-15 200
2 103350016 58 Male Chile
Canela,
2007-03-16 220
3 103402366 51 Female Pernambuco
Buique, for 40 years
2007-05-01 180
4 801603 43 Male Hidalgo, México 2008-02-08 202
5 801604 48 Male Hidalgo, México 2008-02-08 202
3
1
2
4 y 5
3
T. cruzi IT. cruzi IIaT. cruzi IIbT. cruzi IIcT. cruzi IIdT. cruzi IIe
Linajes filogenéticos deTrypanosoma cruzi
Adaptado de Souto et al. 1996;Fernandes et al. 1998; Brisse et al.
2000, 2004.
T. cruzi IT. cruzi IIaT. cruzi IIbT. cruzi IIcT. cruzi IIdT. cruzi IIe
Linajes filogenéticos deTrypanosoma cruzi
Adaptado de Souto et al. 1996;Fernandes et al. 1998; Brisse et al.
2000, 2004.
1 2 3
1-Have you ever heard about Chagas Disease? Y Y Y
2-Do you know how to recognize a kissing bug? Y Y Y
3-Have you ever lived in a house constructed of wood and mud? N N Y
4-Have you had contact with a kissing bug? N Y Y
5-Have any of your relatives ever had Chagas disease? Y N Y
6-Did you live in the same house with a relative who is positive for Chagas Disease?
N N Y
7-Do you know any case of Chagas Disease in the region where you have born or where you have lived?
N Y Y
8-Have you ever received blood transfusion? N N N
9-Have you ever been to any Chagas endemic region? N N N
10-Have you ever had any clinical symptoms for Chagas Disease ? N N Y
11-Are you under medical treatment ? N N Y
12-Have you ever done an electrocardiogram (EKG)? Y Y Y
Epidemiological QuestionnaireEpidemiological Questionnaire
Raw materialRaw material - - ReactivityReactivity
ID
Elisa cruzi
OD/CO
Chagatek
OD/CO
Bioschile
OD/CO
Imuno cruzi
Titre Used
volume
103362946200 ml
9.36Epd: 1/128
6.19Epd: 1/32
4.02Epd: 1/128
1/160 80 ml
103350016220 ml
8.31Epd: 1/128
6.37Epd: 1/64
4.24Epd: 1/128
1/320 120 ml
103402366180ml
7.97Epd: 1/64
5.21Epd: 1/32
3.35Epd: 1/64
1/160 60 ml
801603202 ml
4.71Epd: 1/16
5.03Epd: 1/16
3.15Epd: 1/32
1/160 2 ml
801604202 ml
5.37Epd: 1/64
5.10Epd: 1/64
3.25Epd: 1/128
1/320 2 ml
Prototype = 260ml of positive + 1240 ml of negative plasma from 7 donors units.
(4.8 times diluted.)
Epd = end point dilution (OD/CO) > 1
Raw material - serial dilution OD/CO ratioRaw material - serial dilution OD/CO ratio
Elisa cruzi 103362946 103350016 103402366 801603 801604Dilution DO/CO DO/CO DO/CO DO/CO DO/CO
Pure 9,362 8,312 7,965 4,708 5,369 1/2 8,546 7,646 7,688 4,115 5,738 1/4 6,885 7,192 6,769 2,962 4,846 1/8 5,219 5,758 5,535 2,154 3,931
1/16 3,462 4,481 3,908 1,496 3,158 1/32 2,777 3,373 2,388 0,927 2,477 1/64 1,858 2,131 1,438 0,596 1,612 1/128 1,273 1,465 0,935 0,431 0,842 1/256 0,835 0,769 0,635 0,369 0,762 1/512 0,615 0,546 0,473 0,281 0,492
1/1024 0,465 0,335 0,358 0,262 0,415
Chagatek 103362946 103350016 103402366 801603 801604Dilution DO/CO DO/CO DO/CO DO/CO DO/CO
Pure 6,187 6,368 5,213 5,032 5,097 1/2 5,735 6,065 4,735 4,213 4,600 1/4 4,503 5,342 3,600 2,961 3,819 1/8 3,181 3,929 2,465 2,052 2,955
1/16 2,277 3,542 1,639 1,329 2,806 1/32 1,471 2,194 1,097 0,884 1,561 1/64 0,929 1,335 0,735 0,639 1,032 1/128 0,697 0,890 0,542 0,490 0,677 1/256 0,529 0,639 0,374 0,368 0,452 1/512 0,413 0,413 0,374 0,374 0,381
1/1024 0,374 0,387 0,355 0,381 0,323
Bioschile 103362946 103350016 103402366 801603 801604Dilution DO/CO DO/CO DO/CO DO/CO DO/CO
Pure 4,024 4,235 3,346 3,147 3,246 1/2 3,831 4,000 3,164 2,673 3,132 1/4 3,629 3,559 2,904 2,377 2,814 1/8 3,039 3,211 2,590 1,836 2,156
1/16 2,452 2,612 2,092 1,327 1,954 1/32 1,958 2,287 1,675 1,158 1,647 1/64 1,518 1,794 1,127 0,748 1,436 1/128 1,184 1,316 0,853 0,537 1,081 1/256 0,842 0,987 0,607 0,436 0,783 1/512 0,610 0,691 0,456 0,357 0,640
1/1024 0,463 0,515 0,346 0,325 0,456
= Prototype
= M2
Clinical Sensitivity and Specificity Clinical Sensitivity and Specificity
Chagas Test Elisa III730 T. cruzi positive blood donor samples
020406080
100120140160
O.D./C.O.
Fre
qu
ency
Elisa cruzi730 T. cruzi positive blood donor sample
0
5
10
15
20
25
30
35
40
45
0
0,6
1,2
1,8
2,4 3
3,6
4,2
4,8
5,4 6
6,6
7,2
7,8
8,4 9
9,6
O.D./C.O.
Fre
quency
Chagas Test Elisa III956 T. cruzi negative Blood donor samples
0
5
10
15
20
25
30
35
0
0,11
0,22
0,33
0,44
0,55
0,66
0,77
0,88
0,99 1,1
1,21
1,32
1,43
1,54
1,65
1,76
1,87
1,98
O.D./C.O.
Fre
quen
cy
Elisa cruzi828 T. cruzi negative blood donor sample
0
10
20
30
40
50
60
70
0
0,11
0,22
0,33
0,44
0,55
0,66
0,77
0,88
0,99 1,
1
1,21
1,32
1,43
1,54
1,65
1,76
1,87
1,98
D.O./C.O.
Fre
qu
ency
Mexico SamplesElisa cruzi
01
23
45
67
Serial Dilution
OD
/CO
801603
801604
M2
Mexico SamplesChagatek
0
1
2
3
4
5
6
Serial Dilution
OD
/CO 801603
801604
M2
Mexico SamplesTest Elisa p/ Chagas III
0
1
2
3
4
Serial Dilution
OD
/CO 801603
801604
M2
Elisa cruzi Chagatek Bioschile IFIPure 4,962 5,406 3,143 1/80 1/2 4,792 4,774 3,042 1/40 1/4 4,677 3,619 2,803 1/20 1/8 3,758 2,703 2,287 Negative
1/16 2,612 1,910 2,020 Negative 1/32 1,896 1,297 1,616 Negative 1/64 1,362 0,865 1,309 Negative 1/128 0,923 0,542 1,046 Negative 1/256 0,581 0,477 0,768 Negative 1/512 0,435 0,413 0,579 Negative
M2M2
OD/CO ratio
Brazil SamplesElisa cruzi
0123456789
10
Pure
1/2
1/4
1/8
1/1
6 1
/32
1/6
4
1/1
28
1/2
56
1/5
12
1/1
024
Serial Dilution
OD
/CO
103362946
103350016
103402366
Prototype
Brazil SamplesChagatek
0
1
2
3
4
5
6
7
Serial Dilution
OD
/CO
103362946
103350016
103402366
Prototype
Brazil SamplesTest Elisa P/ Chagas III
0
1
2
3
4
5
Pure
1/2
1/4
1/8
1/1
6 1
/32
1/6
4
1/1
28
1/2
56
1/5
12
1/1
024
Serial Dilution
OD
/CO
103362946
103350016
103402366
Prototype
Elisa cruzi Chagatek Bioschile IFIPure 5,723 3,910 3,252 1/40 1/2 5,004 2,994 2,704 1/20 1/4 3,435 1,935 2,086 Negative 1/8 2,262 1,219 1,711 Negative
1/16 1,338 0,794 1,349 Negative 1/32 0,862 0,568 0,958 Negative 1/64 0,592 0,452 0,658 Negative
PrototypePrototype
OD/CO ratio
Evaluating the Prototype Evaluating the Prototype • EQAS to evaluate performance in loco.
• Send 1.8ml of the prototype serum to 25 reference centers in 16 countries in LA.
• Included 4 other non diluted not pooled samples to the same panel.
• Sep 2007 (OPS0207), Apr 2008 (OPS0108) and Sep 2008 (OPS0208).
Data from Latin America Reference Centers – PAHO Regional EQAS
Prototype X 2 times diluted Reactivity by Kit April 2008
0
2
4
6
8
10
12
14
16
2a 3a 4a 22a 9
10b 26 18
a17
a24
a 21 21 13a 26 14
b28
b 5b 8b 7b 1b 23b
20b
16b
24a
Results
OD
/CO
Prototype Diluted 2X - - - - - DO/CO mean
Chagas Test Elisa III
Chagatest Elisa
Wiener Recomb. Chagatek
Biokit Elisa cruzi
UCR IICS Col. Chile
Bioschile
Cut offCut off
Reactivity
0
2
4
6
8
10
12
14
16
18
20
13a
17a
18b
18a
17b 21 22
b 21 19 13a
17a
18b
20b 6
14a
28a 1b 14
a28
b11
b13
a14
b
Laboratory
OD
/CO
Prototype Mean
Diluted 2X Mean
Chagatest Elisa Wiener CV = 35% Chagatest Elisa Recombinante
Wiener CV = 27%
ChagascreenCV = 9%
Chagatek CV = 31%
Data from Latin America Reference Centers – PAHO Regional EQAS
Sep 2007 Apr 2008 Sep 2008
Data from Latin America Reference Centers – PAHO Regional EQAS
Reactivity
0
1
2
3
4
5
6
7
8
9
10
23a
23a
23a 7a 7a 1b 3a 27 3a 4b 9 27 1a 2b 4a 5b 26 10
a 5a 8b 8a 10a
Laboratory
OD
/CO
Prototype Mean
Diluted 2X Mean
Elisa cruziCV = 16% Chagastest Elisa III
CV = 24%BiokitCV = 10% Test Elisa p/ Chagas
CV = 14%
Sep 2007 Apr 2008 Sep 2008
Data from Latin America Reference Centers – PAHO Regional EQAS
Reactivity
0
1
2
3
4
5
22a 22a 22b 20a 20b 20a 20b 16a 16b 16a 16b 16a 16b 16c 24a 24a 24b 24a 24b 25 25
Laboratory
OD
/CO
Prototype Mean
Diluted 2X Mean
PeroxidasaCV = 4,3 %
Colombia
Chile EIACV =11 %
Chagas Test IICSCV = 11 %
LSU-ICMRTCV = 75%
Sep 07 Apr 2008 Sep 08
Stability of the Prototype Kit / Semester
02468
101214
Test
Elis
a p/
Cha
gas
Elisa
cruz
i
Chaga
s Te
st E
lisa
III
Chaga
test
Elis
a
Chaga
test
Elis
a Rec
Bioelis
a Cha
gas
Chaga
s Te
st II
CS ELI
SA
Chaga
s EIA
Chaga
tek
ELISA
Chaga
s cr
een
Chaga
s Elis
a Per
oxida
sa
Chaga
s EIA
Colo
mbia
Test
Elis
a p/
Cha
gas
(UCR)
Chaga
s Pha
rmat
est
Kit
OD
/CO
Sep 2007 April 2008 Sep 2008
Data from Latin America Reference Centers – PAHO Regional EQAS
Data from Latin America Reference Centers – PAHO Regional EQAS
Prototype X 2 times diluted April 2008
0
2
4
6
8
10
Test
Elis
a p/
Cha
gas
Elisa
cruz
i
Chaga
s Te
st E
lisa
III
Chaga
test
Elis
a
Chaga
test
Elis
a Rec
Bioelis
a Cha
gas
Chaga
s Te
st II
CS ELI
SA
Chaga
s EIA
Chaga
tek
ELISA
Chaga
s cr
een
Chaga
s Elis
a Per
oxida
sa
Chaga
s EIA
Colo
mbia
Test
Elis
a p/
Cha
gas
(UCR)
Chaga
s Pha
rmat
est
Imun
ocru
zi IF
I
Polich
aco
HAI Cha
gas
Kit
OD
/CO
Prototype Diluted 2x
Stability of Donor Sample (not pooled not diluted)
02468
101214
Test
Elis
a p/
Cha
gas
Elisa
cruz
i
Chaga
s Te
st E
lisa
III
Chaga
test
Elis
a
Chaga
test
Elis
a Rec
Bioelis
a Cha
gas
Chaga
s Te
st II
CS ELI
SA
Chaga
s EIA
Chaga
tek
ELISA
Chaga
s cr
een
Chaga
s Elis
a Per
oxida
sa
Test
Elis
a p/
Cha
gas
(UCR)
Chaga
s Colo
mbia
Chaga
s Pha
rmat
est
Imun
ocru
zi IF
I
Polich
aco
HAI Cha
gas
Kit
OD
/CO
Sep 2007 April 2008
Stability of prototype
0
2
4
6
8
10
12
14
Test
Elis
a p/
Cha
gas
Elisa
cruz
i
Chaga
s Te
st E
lisa
III
Chaga
test
Elis
a
Chaga
test
Elis
a Rec
Bioelis
a Cha
gas
Chaga
s Te
st II
CS ELI
SA
Chaga
s EIA
Chaga
tek
ELISA
Chaga
s cr
een
Chaga
s Elis
a Per
oxida
sa
Chaga
s EIA
Colo
mbia
Test
Elis
a p/
Cha
gas
(UCR)
Chaga
s Pha
rmat
est
Imun
ocru
zi IF
I
Polich
aco
HAI Cha
gas
Kit
OD
/CO
Sep 2007 April 2008
Data from Latin America Reference Centers PAHO Regional EQAS
Prototype stability by temperature / timeElisa cruzi
4,0
4,2
4,4
4,6
4,8
5,0
5,2
5,4
5,6
5,8
6,0
nov-07 jan-08 mar-08 mai-08 jul-08 set-08 nov-08
Assay Date
Me
an
O
D/C
O
-20ºC
4 ºC
22 ºC
37 º C
Mean
Mean
Mean
Mean
Prototype volume available = 1.4 liters
2 times dilution = 2.8 liters
It is possible to obtain a total of 6 liters
Units used mL available mL
1 80 120
2 120 100
3 60 120
4 2 200
5 2 200
Volume Volume
Mexico Units
M2 volume available = 400 mL
4 times dilution = 1.6 liters
ConclusionConclusion
• The mixture of 3 positive samples (from south of Latin America) diluted 4.8 times in negative samples have produced a prototype that presented stability at –20 ºC.
• We need to define the reactivity of the cut off value. Here we have used the dilution that is IIF = 1/20.
• Reactivity of the prototype diluted 2 times were 2 to 4 times de cutoff value in most of the tests evaluated and the IIF = 1/20.
• Perhaps we should submit this prototype to RIPA, Western Blot and Abbott Immunoassay.
Reactivity
0
2
4
6
8
10
12
14
16
18
20
13a
17b
18a
24b
21
13b
18b
21
8a
28a
26
13a
23b
7a
1a
4a
27
4a
10a
1a
3b 6 26 3 7a
10a
22a
20b
16b
16c
24a
Laboraotry
OD
/CO
Prototype Mean
Diluted 2X Mean
Reactivity
0
2
4
6
8
10
12
14
16
18
20
13a
17b
18a
24b
21
13b
18b
21
8a
28a
26
13a
23b
7a
1a
4a
27
4a
10a
1a
3b 6 26 3 7a
10a
22a
20b
16b
16c
24a
Laboraotry
OD
/CO
Prototype Mean
Diluted 2X Mean
1
2
Reactivity
0
2
4
6
8
10
12
14
16
18
20
13a
17b
18a
24b
21
13b
18b
21
8a
28a
26
13a
23b
7a
1a
4a
27
4a
10a
1a
3b 6 26 3 7a
10a
22a
20b
16b
16c
24a
Laboraotry
OD
/CO
Prototype Mean
Diluted 2X Mean
4
56 7 8 9 10
11 12 13
3
1
2
Sep 2007 April 2008 Sep 2008Kit DO/CO DO/CO DO/CO
1 Chagas creen 11,947 - -2 Chagatest Elisa 9,507 8,881 8,1003 Chagatest Elisa Rec 7,470 8,882 8,2074 Chagatek ELISA 5,635 6,341 6,0635 Elisa cruzi 4,704 3,853 4,9906 Bioelisa Chagas 3,264 3,506 -7 Chagas Test Elisa III 3,023 3,088 2,8408 Test Elisa p/ Chagas 3,079 2,871 2,9019 Chagas Elisa Peroxidasa 3,048 - 3,110
10 LSU-ICMRT 4,399 0,930 -11 Chagas Test IICS ELISA 2,417 1,996 2,44012 Chagas EIA 1,920 1,588 1,43613 Chagas EIA Colombia - 1,430 1,020
Reference Serum
Data from Latin America Reference Centers PAHO
Regional EQAS